Suven Life Sciences in a notification to the stock exchanges on Thursday said it has initiated Phase 1 clinical trials and first dosing of a chemical entity intended for the treatment of major depressive disorder (MDD). The topline results from the study are expected during the January-March 2018 quarter, it further said. Suven Life Sciences, which had submitted the Investigational New Drug Application to conduct Phase 1 clinical trial for MDD under 505(1) of the Federal Food, Drug and Cosmetic Act (FDCA, USA), said the global anti-depressant market is valued at over $20 billion. The stock closed flat at ₹174.15 on the NSE.